Hyundai Bioscience announced positive phase 2 clinical study results of the global blockbuster candidate for the COVID-19 antiviral drug

Posted on by

– Hyundai Bioscience announcing the receipt of the phase 2 clinical study report of XaftyTM and its plans for the emergency use authorization – Planning fast track process in oversea countries to enter the global market SEOUL, South Korea, May 2, 2023 /PRNewswire/ — Hyundai Bioscience…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.